Improvement initiative in LDL-C management in Saudi Arabia: A call to action

IJC Heart and Vasculature - Tập 31 - Trang 100667 - 2020
Mirvat Alasnag1, Zuhier Awan2, Ahmed Al Ghamdi3, Hind Al Modaimeigh4, Mostafa Al Shemiri5
1Catheterization Laboratory, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia
2Medicine, Biochemistry and Molecular Genetic, Clinicial Biochemistry Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
3Pharmacoeconomics and Health Policy, Clinical Pharmacy Department, College of Pharmacy, King Saud University, Saudi Arabia
4Cardiology Clinical Pharmacy Specialist, Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia
5Cardiac Science, College of Medicine, King Saud University, Saudi Arabia

Tài liệu tham khảo

Roth, 2017, Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015, JACC., 70, 1, 10.1016/j.jacc.2017.04.052

Turk-Adawi, 2018, Nat Rev Cardiol., 15, 106, 10.1038/nrcardio.2017.138

Gehani, A. A., Al-Hinai, A. T., Zubaid, M., et al. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. Eur J Prev Cardiol. 21;400-410.

Grundy, 2018, AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, JACC., 2019, 73

Zubaid, 2008, Clinical presentation and outcomes of acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE), Saudi Med J, 29, 251

Alhabib, 2012, Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the Second Gulf Registry of Acute Coronary Events (Gulf RACE-2), Ann Saudi Med, 32, 9, 10.5144/0256-4947.2012.9

Mohammed Basulaiman MDa, 2013, Charbel El Bcheraoui PhD, MSc b, Marwa Tuffaha MD et al, Hypercholesterolemia and its associated risk factors Kingdom of Saudi Arabia, Ann. Epidemiol., 24, 801

Alsheikh-Ali, 2014, Cardiovascular Risk Factor Burden in Africa and the Middle East: The Africa Middle East Cardiovascular Epidemiological (ACE) Study, PLoS ONE, 9, 10.1371/journal.pone.0102830

Ahmed, 2017, Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study, J Saudi Heart Assoc., 27, 235, 10.1016/j.jsha.2017.03.004

Al-Rasadi, 2020, The Gulf Familial Hypercholesterolemia Registry (Gulf FH): Design, Rationale and Preliminary Results, Curr Vasc Pharmacol., 18, 57, 10.2174/1570161116666181005125459

Maron DJ, et al. Circulation. 2000;101:207-213; *CTTC. Lancet. 2010; 376(9753):1670-1681.

François Mach, Colin Baigent, Alberico L Catapano, et al. ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and 111–188.

Piepoli, 2016, Heart J., 37, 2315, 10.1093/eurheartj/ehw106

Ford, 2016, Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of scotland coronary prevention study, Circulation, 133, 1073, 10.1161/CIRCULATIONAHA.115.019014

Ference, 2017, Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel, Eur Heart J., 38, 2459, 10.1093/eurheartj/ehx144

Ridker, 2008359212195, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med., 10.1056/NEJMoa0807646

Cimmino, 2016, Evolving concepts in LDL-lowering strategies: Are we there?, J. Clin. Exp. Cardiol., 7, 10.4172/2155-9880.1000468

Vodnala, 2012, Secondary causes of dyslipidemia, Am J Cardiol., 110, 823, 10.1016/j.amjcard.2012.04.062

Stroes, 2015, Statin-associated muscle symptoms: Impact on statin therapy-european atherosclerosis society consensus panel statement on assessment, aetiology and management, Eur. Heart J., 36, 1012, 10.1093/eurheartj/ehv043

Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N. Engl. J. Med., 372, 2387, 10.1056/NEJMoa1410489

Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N. Engl. J. Med., 376, 1713, 10.1056/NEJMoa1615664

Toth, 2017, Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia, J. Am. Heart Assoc., 6, 10.1161/JAHA.116.005367

Steg PG. Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab - ODYSSEY OUTCOMES. March 10, 2018.

Raal, 2012, Circulation, 126, 2408, 10.1161/CIRCULATIONAHA.112.144055

Santos, 2020, Long-Term Evolocumab In patients With Familial Hypercholesterolemia, J. Am. Coll. Cardiol., 75, 565, 10.1016/j.jacc.2019.12.020

Giugliano, 2017, EBBINGHAUS Investigators. Cognitive Function in a Randomized Trial of Evolocumab, N Engl J Med, 377, 633, 10.1056/NEJMoa1701131

Ginsberg, 2018, Efficacy and safety of alirocumab in individuals with diabetes mellitus: pooled analyses from five placebo-controlled phase 3 studies, DiabetesTher., 9, 1317

Sabatine, 2017, Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, Lancet Diabetes Endocrinol., 5, 941, 10.1016/S2213-8587(17)30313-3

Jeffery, 2015, Interventions to improve adherence to cardiovascular disease guidelines: a systematic review, BMC family practice, 16, 147, 10.1186/s12875-015-0341-7

Green, 2003, Clinical practice guidelines: a guide to better practice, not a recipe for uniformity, Australian Journal of Physiotherapy, 49, 3, 10.1016/S0004-9514(14)60182-3

Bassand, 2005, Evidence-based vs. ‘impressionist’medicine: how best to implement guidelines, Eur. Heart J., 26, 1155, 10.1093/eurheartj/ehi262

Woolf, 1999, Potential benefits, limitations, and harms of clinical guidelines, BMJ, 318, 527, 10.1136/bmj.318.7182.527

Yusuf, 2011, Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey, Lancet, 378, 1231, 10.1016/S0140-6736(11)61215-4

Gehani, 2014, Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study, Eur J Prev Cardiol, 21, 400, 10.1177/2047487312465525

Arafah, 2014, Centralized pan-Middle East survey on the undertreatment of hypercholesterolemia: results from the CEPHEUS study in Arabian Gulf countries, Angiology, 65, 919, 10.1177/0003319713512414

Al Sifri, 2014, Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment, PLoS One, 9, 10.1371/journal.pone.0084350

Al-Omran, 2012, Vascular Health and Risk Management, 8, 349, 10.2147/VHRM.S32783

https://www.globalhealthsaudi.com/content/dam/Informa/globalhealthsaudi/downloads/GHE19-KSA-HEALTHCARE-INDUSTRY-OVERVIEW.

Al-Omar, 2019, What local experts expect from a health technology assessment (HTA) entity in Saudi Arabia: workshop conclusions, Expert review of pharmacoeconomics & outcomes research, 1

Neumann, 2015, Measuring the value of prescription drugs, N. Engl. J. Med., 373, 2595, 10.1056/NEJMp1512009

Porter, 2010, What is value in health care, N Engl J Med, 363, 2477, 10.1056/NEJMp1011024

Thông tin
Thông tin xuất bản

IJC Heart and Vasculature

Tập 31

100667

Thông tin tác giả